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Blunted Evoked Prouroguanylin Endocrine Secretion in
Chronic Constipation
Scott A. Waldman, MD, PhD1, Renata Tenenbaum2, Henry C. Foehl, PhD3, Peter Winkle, MD4 and Patrick Griffin, MD2
OBJECTIVES:

Prouroguanylin (ProUGN) in the intestine is cleaved to form uroguanylin (UGN), which stimulates
guanylate cyclase C (GUCY2C), inducing cyclic guanosine monophosphate signaling. Paracrine release
regulates fluid secretion, contributing to bowel function, whereas endocrine secretion evoked by eating
forms a gut-brain axis, controlling appetite. Whereas hormone insufficiency contributes to hyperphagia
in obesity, its contribution to the pathophysiology of constipation syndromes remains unexplored. Here,
we compared circulating ProUGN and UGN in healthy subjects and in patients with chronic idiopathic
constipation (CIC) and patients with irritable bowel syndrome with constipation (IBS-C).

METHODS:

Circulating ProUGN and UGN levels were measured in 60 healthy subjects, 53 patients with CIC, and
54 patients with IBS-C. After an overnight fast, the participants ingested a standardized meal; blood
samples were drawn at fasting and at 30, 60, and 90 minutes thereafter, and hormone levels were
quantified by enzyme-linked immunosorbent assay.

RESULTS:

Fasting ProUGN levels were >30% lower in patients with CIC and those with IBS-C compared with
healthy subjects regardless of age, sex, or disease state. After eating, ProUGN levels increased
compared with fasting levels, although the rate of change was slower and maximum levels were lower in
patients with CIC and those with IBS-C. Similarly, fasting UGN levels were lower in patients with CIC and
those with IBS-C compared with healthy subjects. However, unlike ProUGN levels, UGN levels did not
increase after eating.

DISCUSSION:

These observations support a novel pathophysiologic model in which CIC and IBS-C reflect
a contribution of ProUGN insufficiency dysregulating intestinal fluid and electrolyte secretion.

TRANSLATIONAL This study suggests that CIC and IBS-C can be treated by oral GUCY2C hormone replacement. Indeed,
IMPACT:
these observations provide a mechanistic framework for the clinical utility of oral GUCY2C ligands like

plecanatide (Trulance) and linaclotide (Linzess) to treat CIC and IBS-C.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A66
Clinical and Translational Gastroenterology 2019;10:e-00016. https://doi.org/10.14309/ctg.0000000000000016

INTRODUCTION
Functional gastrointestinal (GI) disorders aﬀect a substantial
number of patients worldwide, accounting for a signiﬁcant percentage of healthcare spending globally (1–5). Whereas their
clinical and economic impact is considerable, the mechanisms
underlying these related disorders remain incompletely deﬁned
(1,4). In that context, chronic idiopathic constipation (CIC) and
irritable bowel syndrome with constipation (IBS-C) are two of the
most prevalent functional GI disorders (1). IBS is characterized by
recurrent episodes of abdominal pain, with at least 1 episode per
week in the last 3 months, on average, of pain related to defecation,

associated with a change in the frequency of stool, or associated with
a change in the form of stool (3). IBS can be subtyped by the
predominant stool form: constipation (IBS-C), diarrhea (IBS-D), or
mixed (IBS-M) (3,4). Those within the IBS-C subtype experience
hard or lumpy stools more than 25% of the time they defecate and
loose or watery stools less than 25% of the time (2). IBS-C aﬀects
about 1 in 20 people, representing about 5% of the adult population,
in the United States (1,2,5). Similarly, CIC is a complex functional
GI disorder deﬁned by symptoms including fewer than 3 bowel
movements a week and hard-to-pass or incomplete bowel movements (4). In addition to physical symptoms including abdominal
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bloating and discomfort, CIC can adversely aﬀect an individual’s
quality of life, including increasing stress levels and anxiety (6,7).
CIC aﬀects approximately 33 million Americans and an estimated
14% of the global population (1,4,5). Although IBS-C and CIC can
be discriminated based on clinical criteria, there is substantial
overlap in these functional GI disorders (1,2,4,5). These conditions
remain prevalent and consume a disproportionate amount of
healthcare resources including up to $10B in direct costs and $20B
in indirect costs in the United States alone (5). Although their
clinical and economic impact is substantial, precise molecular
mechanisms underlying the pathophysiology of these related disorders remain incompletely deﬁned (1,4).
Guanylate cyclase C (GUCY2C) is an epithelial cell receptor
expressed along the rostral-caudal axis of the intestine from proximal
of the duodenum to the distal rectum (8). It was ﬁrst identiﬁed as the
receptor for heat-stable enterotoxins (STs) produced by enterotoxigenic bacteria that causes diarrheal diseases (9–11). Bacterial
STs represent an example of molecular mimicry with strong structural and functional homologies to endogenous hormones produced
segmentally in the intestine. In that context, uroguanylin (UGN) is
a 16-amino acid peptide that activates GUCY2C with maximum
potency in the slightly acidic (pH 5–6) environments of the duodenum and proximal jejunum (12). UGN is expressed by tuft-like
epithelial cells, primarily in the proximal small intestine, with lower
levels in the stomach, the distal small intestine, and the colorectum
(13,14). By contrast, guanylin is a 15-amino acid peptide that activates GUCY2C in neutral to slightly basic pH environments and is
principally expressed in the colorectum by goblet cells (12–14). Both
peptides undergo paracrine secretion into the intestinal lumen as
unprocessed prohormones that are cleaved to mature forms stabilized by 2 disulﬁde bonds compatible with structural ﬂexibility and
isomerization (8,15–17).
Ligand-receptor interaction activates the intracellular catalytic
domain of GUCY2C, which converts guanosine triphosphate to
cyclic guanosine monophosphate (cGMP) (8,18). In the proximal
small intestine, cGMP accumulation induced by UGN activates
signaling intermediates, including protein kinases, whose phosphotransferase activities regulate downstream eﬀectors, including
the cystic ﬁbrosis transmembrane conductance regulator and
sodium-hydrogen exchanger, producing ﬂuid and electrolyte secretion essential to normal bowel function (18,19). Outside these
local paracrine signaling activities in the intestine, there is an
emerging paradigm in which a novel GUCY2C endocrine gutbrain axis regulates feeding, energy and metabolic homeostasis,
and body weight. In that context in mice and humans, ingestion of
food evokes endocrine secretion of prouroguanylin (ProUGN)
from the small intestine into the circulation (20–25). Circulating
ProUGN, but not proguanylin, is processed by the hypothalamus
to the mature UGN hormone (25). UGN binds to and activates
GUCY2C expressed in the hypothalamus, inducing cGMP accumulation (23,25). In turn, hormone activation of central GUCY2CcGMP signaling induces hypothalamic neuronal activity associated
with satiety, decreasing feeding (22,23,25,26).
Beyond intestinal ﬂuid and electrolyte secretion and central regulation of appetite and satiety, the GUCY2C-hormone axis has
emerged as a key component of physiologic mechanisms modulating
intestinal barrier function, inﬂammation, visceral pain, and tumorigenesis (19,27–36). Furthermore, disruptions in GUCY2C signaling
speciﬁcally involving hormone insuﬃciency have been linked to the
pathophysiologic mechanisms underlying inﬂammatory bowel diseases, colorectal cancer, and obesity, and the metabolic syndrome
Clinical and Translational Gastroenterology

(23,34,36–40). Moreover, genetic mutations that result in loss or gain
of function of GUCY2C are associated with constipation or diarrhea,
respectively (41–44). Taken together, these observations raise the
intriguing possibility that the GUCY2C paracrine signaling axis may
play a mechanistic role in chronic constipation syndromes like CIC
and IBS-C. Indeed, as in other diseases in which silencing of
GUCY2C reﬂects hormone loss (23,34,36–40), it is tempting to
speculate that an insuﬃciency of ProUGN, at least in part, contributes to the pathophysiology of chronic constipation. Here, we exploit
evoked endocrine secretion of ProUGN by eating (20,25) and the
direct relationship between circulating and epithelial cell levels of the
hormone (20,23) to assess intestinal GUCY2C hormone production
in patients with CIC or those with IBS-C.

METHODS
Study design

This was a phase 0 exploratory 1-day study to evaluate the eﬀect of
a standardized meal on circulating ProUGN and UGN levels in
healthy volunteers and in patients with functional GI disorders.
The study was designed to test the hypothesis that circulating levels
of ProUGN and UGN evoked by feeding were reduced in patients
with CIC and those with IBS-C compared with normal, healthy
volunteers. The study composed of 3 populations of subjects enrolled at a single site and identiﬁed in an investigator’s database
(Figure 1): normal, healthy men and women, aged 18–80 years,
without a history or evidence of chronic disease (n 5 60); male and
female patients with CIC deﬁned by modiﬁed Rome III functional
constipation criteria, aged 18–80 years, who had not taken any
treatments in the 14 days before enrollment (n 5 53); and male and
female patients with IBS-C deﬁned by Rome III criteria using the
modular questionnaire, aged 18–85 years, who had not taken any
treatments in the 14 days before enrollment (n 5 54) (45). Previous
drug histories including the use of, and responses to, oral GUCY2C
agonists were not collected as part of the study. After obtaining
informed consent, the participants underwent prescreening with
an interview, physical examination, and laboratory assessment to
eliminate those with conditions that alter circulating ProUGN
levels, including heart failure, renal failure, or the nephrotic syndrome (46–48). Enrolled participants were admitted to the clinical
research unit and subjected to an overnight (12 hours) fast. In the
morning, the participants consumed a standardized meal of 750
calories (49 g of fat, 25 g of protein, 53 g of carbohydrate, and 1.49 g
of sodium) within 15 minutes (25). Blood samples were drawn
immediately before (0 minutes) and 30, 60, and 90 minutes after
initiating the meal. After collection of the last blood sample, the
participants underwent post-study evaluation, including an interview and physical examination, after which they were discharged. The study was approved by the Alpha IRB, 1001 Avenida
Pico, Suite C, #497, San Clemente, California.
Primary endpoint

The primary endpoint of the study is the circulating level of
ProUGN and UGN, before and after a standardized meal, in
healthy subjects and in patients with CIC and those with IBS-C.
Primary and exploratory analyses

The primary analysis is the comparison of the time course of
mean concentration levels of circulating ProUGN and UGN.
Exploratory analyses include comparisons between healthy volunteers and patients with CIC and those with IBS-C of: maximum
VOLUME 10 | JULY 2019 www.clintranslgastro.com

3

FUNCTIONAL GI DISORDERS

Prouroguanylin in Chronic Constipation

Figure 1. Flowchart describing participant recruitment, study flow, assessments, and timing.

concentration levels of ProUGN and UGN, the rate of change in
ProUGN and UGN concentration levels, and the diﬀerences in
ProUGN and UGN maximum concentration levels and rates of
change based on gender and age.
American College of Gastroenterology

Circulating ProUGN and UGN levels

Primary and exploratory analyses focused on the concentration of
ProUGN and UGN in the circulation. Blood samples were collected at prespeciﬁed time points into tubes containing 3.2%
Clinical and Translational Gastroenterology
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Table 1. Demographic characteristics at screening (baseline)
Healthy volunteers
(n 5 60)

Patients with CIC
(n 5 53)

Patients with IBS-C
(n 5 54)

60

53

54

Male

38 (63.3)

21 (39.6)

30 (55.6)

Female

22 (36.7)

32 (60.4)

24 (44.4)

60

53

54

37.7 (10.9)

42.5 (14.2)

35.7 (12.5)

38.5

43.0

32.0

30.5, 46.5 (40)

31.0, 54.0 (52)

27.0, 47.0 (49)

40

52

49

Total n

60

53

54

White

39 (65.0)

25 (47.2)

32 (59.3)

Black

15 (25.0)

24 (45.3)

15 (27.8)

Asian

6 (10.0)

4 (7.5)

7 (13.0)

Characteristic

P Value

Gender, n (%)
Total n

0.041a

Age
Total n
Mean (SD)
Median
Q1, Q3 (range)
Range

0.019b,c

Race, n (%)

0.179a

Ethnicity, n (%)
Total n

60

53

54

Hispanic or Latino

27 (45.0)

15 (28.3)

19 (35.2)

Non-Hispanic

33 (55.0)

38 (71.7)

35 (64.8)

0.190a

Height
Total n
Mean (SD)

58

52

48

171.5 (9.6)

169.2 (10.5)

171.4 (10.2)

Median
Q1, Q3 (range)

171.5

168.9

170.2

165.1, 177.8 (38)

161.3, 176.5 (38)

163.8, 177.8 (43)

58

52

48

76.9 (13.2)

74.8 (16.1)

83.6 (20.9)

77.1

71.4

78.2

66.2, 86.2 (62)

63.5, 81.2 (78)

70.3, 91.9 (88)

0.409b

BMI (kg/m2)
Total n
Mean (SD)
Median
Q1, Q3 (range)

0.028b,c

BMI, body mass index; CIC, chronic idiopathic constipation; IBS-C, irritable bowel syndrome with constipation.
a
Fisher exact test.
b
ANOVA for comparison of group means.
c
Tukey multiple comparison test for differences in CIC vs IBS-C.

sodium citrate, immediately inverted several times, and then
placed on ice. Samples were centrifuged at 1,300 relative centrifugal force at 4 °C for 10 minutes. Supernatant serum was
removed to a fresh, precooled, labeled tube for distribution into
cryovials and storage at 280 °C. Human ProUGN levels in freshly
thawed plasma, assayed in duplicate, were measured by enzymelinked immunosorbent assay using a quantitative sandwich enzyme immunoassay kit from BioVendor (Brno, Czech Republic),
analytically validated previously (20,48,49). Human UGN levels
were quantiﬁed by enzyme-linked immunosorbent assay using
a kit from Biomatik (Wilmington, DE). ProUGN and UGN levels
were quantiﬁed by Charles River (San Diego, CA). Brieﬂy,
standards and samples were added to microplate wells coated
Clinical and Translational Gastroenterology

with polyclonal antihuman ProUGN antibody. After incubation (60 minutes) and washing, a biotin-labeled polyclonal antihuman ProUGN antibody was added to the wells
(60 minutes), followed by another washing step, then by incubation (30 minutes) with streptavidin-horseradish peroxidase conjugate, and a ﬁnal washing step. The addition of the
substrate 3,30,5,50-tetramethylbenzidine allows the enzyme
activity proportional to the concentration of ProUGN to be
measured spectrophotometrically.
Statistical analyses

A summary of baseline demographic parameters (age, gender,
race, ethnicity, height, weight, and body mass index) is presented
VOLUME 10 | JULY 2019 www.clintranslgastro.com

in Table 1, by participant group (healthy volunteers, patients with
CIC, patients with IBS-C, and CIC and IBS-C patients combined).
A summary of baseline clinical laboratory parameters (hematology, serum chemistry, and urinalysis) is presented in Supplementary Table 1 (see Supplementary Digital Content 1, http://
links.lww.com/CTG/A66). Statistical summaries and analyses
were performed using SAS version 9.4 (SAS Institute). All tests of
statistical signiﬁcance are 2-sided and performed at the 0.05 level
of signiﬁcance. P values presented are intended for informational
purposes only; no adjustments have been made for repeated
testing.

RESULTS
Subject characteristics

For this study, 67 healthy volunteers and 124 patients (diagnosed
with either CIC or IBS-C) were screened, with 7 healthy subjects
and 17 patients with CIC or IBS-C determined to be screen failures (Figure 1). The enrolled 60 healthy subjects, 53 patients with
CIC, and 54 patients with IBS-C did not diﬀer signiﬁcantly by
race, ethnicity, or height (Table 1). There was a greater proportion
of women in patient cohorts (P 5 0.041), patients with CIC were
slightly older (P 5 0.019), and patients with IBS-C had a modestly
increased body mass index (P 5 0.028), consistent with established demographic characteristics for these populations
(Table 1) (2–4). Physical examinations and laboratory analyses
revealed no clinically signiﬁcant ﬁndings and no evidence of renal
or cardiovascular disease (see Table 1, Supplementary Digital
Content 1, http://links.lww.com/CTG/A66).
Fasting hormone levels

This is the ﬁrst report of the simultaneous quantiﬁcation of
ProUGN and UGN levels in humans. Mean fasting ProUGN
concentration levels were substantially greater than mean fasting
UGN concentration levels across all diagnosis, age, and gender
subgroups, aligning with the results in rodents (12,28–30). Fasting ProUGN and UGN levels were lower in patients with chronic
constipation syndromes, compared with normal subjects
(Figure 2). The diﬀerence in mean fasting ProUGN levels in
patients with chronic constipation was 583 pg/mL (95% conﬁdence interval: 406–761; P , 0.0001). Similarly, the diﬀerence in
mean fasting UGN levels in patients with chronic constipation
was 112 pg/mL (95% conﬁdence interval: 74–150; P , 0.0001).
There were no diﬀerences in fasting ProUGN or UGN levels in
patients with CIC and those with IBS-C (Figure 2a,b). Similarly,
there were no diﬀerences in fasting ProUGN or UGN levels by sex
(Figure 2c,d). Interestingly, there was a diﬀerence in fasting
ProUGN levels but not UGN levels in healthy subjects, but not
constipated patients, by age (Figure 2e,f). Indeed, older healthy
subjects ($41 years) had a mean fasting ProUGN level of 2,159 6
708, whereas younger healthy subjects (#40 years) had a mean
level of 1741 6 495 (P , 0.0127).
Postprandial ProUGN levels

This is the ﬁrst report of postprandial circulating ProUGN levels
in adults. ProUGN levels increased from fasting levels after
a standard meal in all cohorts, in close agreement with the results
obtained in rodents and in adolescent humans (20,25). ProUGN
levels were more than 29% lower (P , 0.0001) at all time points in
patients with chronic constipation syndromes, compared with
normal subjects (Figure 3a; see Figure 1, Supplementary Digital
Content 1, http://links.lww.com/CTG/A66). The rate of change
American College of Gastroenterology

in ProUGN levels was greater in normal subjects compared with
patients with chronic constipation (P , 0.0004; Figures 3a, 4a; see
Figure 1, Supplementary Digital Content 1, http://links.lww.com/
CTG/A66). Moreover, maximum levels of ProUGN were greater
in normal subjects compared with patients with chronic constipation (P , 0.0001; Figures 3a, 5a). There were no diﬀerences
in ProUGN levels (Figure 3b), postprandial rate of change
(Figure 4a), or postprandial maximum concentrations (Figure 5a)
in patients with CIC and those with IBS-C. Similarly, there were
no diﬀerences in the postprandial rate of change in ProUGN by
sex (Figure 4b) or age (Figure 4c). However, healthy women had
higher postprandial levels of ProUGN (P , 0.0193; Figure 3c),
compared with healthy men. Moreover, older ($41 years)
healthy subjects and patients with CIC, but not those with IBS-C,
had higher postprandial ProUGN levels (P , 0.0049, healthy
subjects; P , 0.0016, patients with CIC; Figure 3d), associated
with a greater maximum concentration (P , 0.0325, healthy
subjects; P , 0.0217, patients with CIC; Figure 5c), compared
with younger (#40 years) healthy subjects or patients with CIC.
Postprandial UGN levels

In contrast to ProUGN levels, UGN levels did not increase from
fasting levels after a standard meal in any cohort (Figure 6a). UGN
levels were more than 35% lower (P , 0.0001) at all time points in
patients with chronic constipation syndromes, compared with
normal subjects (Figure 6a). There were no diﬀerences in postprandial UGN levels in patients with CIC and IBS-C (Figure 6b).
Similarly, there were no diﬀerences in postprandial UGN levels by
sex (Figure 6c). However, older patients with IBS-C ($41 years)
had higher postprandial UGN levels (P 5 0.0081) compared with
younger patients with IBS-C (#40 years) (Figure 6d).

DISCUSSION
Here, we reveal for the ﬁrst time that patients with CIC and those
with IBS-C have lower baseline levels of circulating ProUGN
and UGN. Moreover, they have lower evoked increases in circulating ProUGN and UGN induced by feeding. These observations suggest that patients with CIC and those with IBS-C
produce lower levels of ProUGN in the epithelial cells in the
small intestine, the primary source of this hormone in the circulation (8,20,25,50). In that context, the intestinal GUCY2C
paracrine hormone axis regulates ﬂuid and electrolyte secretion,
maintaining intestinal function, including bowel movements
(8,18,19). Taken together, these observations suggest a pathophysiologic paradigm in which functional GI disorders of
chronic constipation, including CIC and IBS-C, may reﬂect
ProUGN insuﬃciency that, in turn, produces inadequate
stimulation of GUCY2C, resulting in incomplete ﬂuid and
electrolyte secretion disrupting normal bowel movements. Indeed, this novel pathophysiologic paradigm suggests that CIC
and IBS-C may, in part, represent a paracrine hormone insuﬃciency syndrome.
A role for GUCY2C in disorders of intestinal secretion has
been described. Indeed, a gain-of-function mutation in GUCY2C
in a Norwegian family has been associated with chronic mild
diarrhea (41). This autosomal dominant mutation in the extracellular domain increases the binding aﬃnity of GC-C for all
ligands. Moreover, the aﬀected family members were more susceptible to IBS, IBD, small bowel obstruction, and esophagitis.
Another gain-of-function group of mutations was linked to
congenital sodium diarrhea, in which GUCY2C is constitutively
Clinical and Translational Gastroenterology
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Figure 2. Fasting serum ProUGN (a, c, e) and UGN (b, d, f) concentrations in healthy volunteers, patients with CIC, and patients with IBS-C by (a and b)
diagnosis (blue, healthy volunteers; red, patients with CIC; green, patients with IBS-C), (c and d) gender (o, male; 1, female), and (e and f) age (s, #40
years; ◊, .40 years). CIC, chronic idiopathic constipation; IBS-C, irritable bowel syndrome with constipation; ProUGN, prouroguanylin; UGN, uroguanylin.

active, elevating cGMP levels in the absence of ligand binding
(42). Of note, the other major cause of congenital sodium diarrhea is loss-of-function autosomal recessive mutations in the
Na1/H1 exchanger, which is a key downstream target of
GUCY2C-cGMP signaling (51). Conversely, inactivating mutations of GUCY2C associated with decreased cGMP production
were discovered in newborns born to families with a history of

meconium ileus (43). Though commonly associated with cystic
ﬁbrosis, meconium ileus is a distinct diagnosis characterized by
neonatal intestinal obstruction. A recent study reported 2 separate autosomal recessive GUCY2C loss-of-function mutations
that cause meconium ileus in unrelated Bedouin families (43).
In 1 family, a missense mutation produced a change in the extracellular ligand binding domain associated with a 40%

Figure 3. Time course of postprandial changes in serum ProUGN concentrations by (a) cohorts (blue, healthy volunteers; yellow, all patients with
constipation), (b) diagnosis (blue, healthy volunteers; red, patients with CIC; green, patients with IBS-C), (c) gender (blue, male; yellow, female), and (d) age
(blue, #40 years; yellow, .40 years). CIC, chronic idiopathic constipation; IBS-C, irritable bowel syndrome with constipation; ProUGN, prouroguanylin.
Clinical and Translational Gastroenterology
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Figure 4. Rate of change in postprandial ProUGN at 90 minutes by (a) diagnosis (blue, healthy volunteers; red, patients with CIC; green, patients
with IBS-C), (b) gender (dark shade, male; light shade, female), and (c) age (dark shade, #40 years; light shade, .40 years). CIC, chronic
idiopathic constipation; IBS-C, irritable bowel syndrome with constipation; ProUGN, prouroguanylin.

decrease in ligand-induced cGMP production. In the second
family, a nonsense mutation inactivated the catalytic domain of
GUCY2C, preventing cGMP production. More recently, lossof-function mutations in GUCY2C were identiﬁed in a Lebanese
family demonstrating altered aﬃnity in receptor ligand binding
(44). Ultimately, these mutations were associated with decreased ﬂuid and electrolyte secretion, resulting in meconium
ileus (43,44). Interestingly, this loss-of-function mutation in
GC-C provides protection against enterotoxigenic diarrhea,
demonstrating the structural speciﬁcity required for the receptor to respond to the relatively rigid molecular structure of
ST, with the extra intramolecular disulﬁde bridge. Indeed, mice
homozygous or heterozygous for inactivating mutations in GC-C
exhibited lower mortality rates in response to ST-induced secretory

diarrhea compared with wild-type animals (52,53). Moreover,
UGN mRNA is elevated in mucosal biopsies in patients with IBS
with diarrhea, compared with healthy subjects (54,55). Taken together, these observations highlight the role of the GUCY2C
paracrine hormone axis, and its regulation of ﬂuid and electrolyte
secretion, in the pathophysiologic mechanisms underlying dysfunctional bowel habits in patients. In that context, they support
the results of the present study suggesting a role for the GUCY2C
paracrine hormone axis in the pathophysiologic mechanisms underlying CIC and IBS-C.
It is noteworthy that silencing the GUCY2C axis by suppression of the hormone, but preservation of the GUCY2C receptor,
expression is a common molecular mechanism that bridges
a number of pathophysiologic mechanisms. Elimination of

Figure 5. Maximum concentration of postprandial ProUGN at 90 minutes by (a) diagnosis (blue, healthy volunteers; red, patients with CIC; green, patients
with IBS-C), (b) gender (dark shade, male; light shade, female), and (c) age (dark shade, #40 years; light shade, .40 years). CIC, chronic idiopathic
constipation; IBS-C, irritable bowel syndrome with constipation; ProUGN, prouroguanylin.
American College of Gastroenterology
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Figure 6. Time course of postprandial changes in serum UGN concentrations by (a) cohorts (blue, healthy volunteers; yellow, all patients with constipation),
(b) diagnosis (blue, healthy volunteers; red, patients with CIC; green, patients with IBS-C), (c) gender (blue, male; yellow, female), and (d) age (blue, #40
years; yellow, .40 years). CIC, chronic idiopathic constipation; IBS-C, irritable bowel syndrome with constipation; UGN, uroguanylin.

guanylin expression, silencing the GUCY2C-cGMP signaling, is an
early and universal event in colorectal tumorigenesis that is conserved across species. Indeed, oral hormone replacement therapy
stimulating GUCY2C-cGMP signaling prevents tumorigenesis in
mice, and this paradigm is being extended to colorectal cancer
chemoprevention in humans (31,32,34,36,38–40,56,57). Similarly,
hyperphagia associated with obesity induces endoplasmic reticulum
stress in the epithelial cells along the rostral-caudal axis of the intestine, which, in turn, suppresses GUCY2C hormone expression
(23,56). In the colorectum, suppression of guanylin expression by
consumption of excess calories is one mechanism contributing to the
relationship between obesity and colorectal cancer, and oral
GUCY2C hormone replacement blocks intestinal tumorigenesis in
the context of diet-induced obesity (56). Similarly, consumption of
excess calories suppresses expression of UGN in the small intestine,
which eliminates endocrine secretion of ProUGN into the circulation, silencing hypothalamic GUCY2C regulating appetite and satiety, in animals and humans (20,23–25,50). Replacement of the lost
endocrine hormone by transgenic expression of UGN in the brain
reduces appetite and weight gain associated with diet-induced obesity (23). Together, these observations underscore the role of hormone loss, but preservation of GUCY2C receptor, expression as
a key molecular mechanism underlying a number of pathophysiologic conditions. Indeed, they support the present studies deﬁning
a role for hormone insuﬃciency silencing GUCY2C as a novel
pathophysiologic mechanism contributing to functional GI disorders like CIC and IBS-C.
Clinical and Translational Gastroenterology

There is a paucity of information regarding circulating levels
of GUCY2C pro- and mature hormones in humans. Limited
previous studies reveal basal levels of ProUGN in adults that were
comparable with the levels reported herein, establishing conﬁdence in these determinations (25,48). Furthermore, they are
similar to basal circulating ProUGN levels quantiﬁed in healthy
adolescents, consistent with the uniformity of ProUGN expression across the age continuum in the present study (20). Evoked
increases in ProUGN induced by feeding in the present study
recapitulate those observed in healthy adults in a limited series
previously and in healthy adolescents (20,25). Interestingly, there
are no reports quantifying the circulating levels of the mature
peptide, UGN, in humans. Here, we report for the ﬁrst time that
circulating levels of UGN are about 10-fold lower than the circulating levels of ProUGN in healthy subjects, recapitulating
results obtained in animals (8,12,28–30). Furthermore, while
feeding evoked increases in ProUGN (20,25), eating did not alter
the circulating levels of UGN in humans. These observations are
consistent with a hypothesis that endocrine (circulating) levels of
ProUGN responsive to feeding reﬂect synthesis and evoked secretion of this hormone by the small intestine (20,23,25,50). By
contrast, circulating levels of UGN may not be evoked products of
intestinal epithelial cells but, rather, reﬂect end-organ proteolysis
of the pro-peptide to the mature hormone.
Although these observations oﬀer potential insights into the
pathophysiologic mechanisms underlying CIC and IBS-C, the
results should be interpreted within the context of the limitations
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Study Highlights
WHAT IS KNOWN

3 Although CIC and IBS-C are common GI disorders, molecular
3
3
3
3

mechanisms contributing to their pathogenesis remain
unknown.
The GUCY2C receptor regulates intestinal secretion.
Overactivation produces diarrhea, whereas signaling
insufficiency produces constipation.
ProUGN produced in the small bowel is secreted into the
intestinal lumen where it is cleaved to the mature UGN
peptide and binds to GUCY2C to stimulate secretion.
Additionally, eating induces ProUGN secretion into the blood,
which circulates to the hypothalamus to activate neuronal
GUCY2C controlling feeding.
We tested the novel hypothesis that chronic constipation
syndromes reflect GUCY2C hormone insufficiency.

WHAT IS NEW HERE

3 Fasting circulating ProUGN and UGN levels were lower in

patients with constipation compared with healthy subjects.

3 After eating, evoked ProUGN levels increased in the
3

circulation at a slower rate, with maximum levels that were
lower in patients with constipation.
In contrast to ProUGN levels, UGN levels did not increase
from fasting levels after eating.

TRANSLATIONAL IMPACT

3 CIC and IBS-C reflect a contribution of ProUGN hormone
insufficiency to intestinal hyposecretion.

3 Evoked circulating levels of ProUGN induced by
3

a standardized meal could be used as an objective test to
identify patients with CIC and IBS-C with hormone
insufficiency who could benefit from the treatment.
CIC and IBS-C can be treated by oral GUCY2C ligand
replacement to mitigate endogenous hormone insufficiency.
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